Thursday, September 23, 2021
8:54 AM EST – BioVaxys Technology Corp. : Announced today that it has initiated what could be a scientifically groundbreaking study on the reduced ACE2 binding capabilities of the hapten-modified spike protein that is the foundation of BVX-0320, the Company’s SARS-CoV-2 vaccine. David Berd , MD, Chief Medical Officer of Biovaxys, explained that “Biovaxys will compare the binding of haptenized spike protein with the non-haptenized. The results could provide evidence that our vaccine has lowered potential for some of the observed serious vaccine side effects.” BioVaxys Technology Corp. (C.BIOV) shares were unchanged at 0.5.
Stocks in Play: BioVaxys Technology Corp., Thu, 23 Sep 2021 08:57:07 EST